BACKGROUND: Recent studies suggest that interleukin-1beta (IL-1beta) stimulates the production of the acute phase protein complement component C3 in human intestinal epithelial cells. The transcription factor NF-kappaB activates different genes involved in the response to cytokines. It is not known if IL-1beta-induced C3 production in the enterocyte is regulated by NF-kappaB. MATERIALS AND METHODS: Cultured Caco-2 cells, a human intestinal epithelial cell line, were treated with one of the NF-kappaB inhibitors, tosyl-lys-chloromethylketone (TLCK), genistein, or pyrrolidine dithiocarbamate (PDTC), or with N-acetyl-leu-leu-norleucinal (LLnL), a proteasome inhibitor known to block the degradation of Ikappabeta, the cytosolic inhibitor of NF-kappaB. Following this treatment, the Caco-2 cells were stimulated with IL-1beta, and C3 levels in the culture medium were measured after 24 h by ELISA. C3 mRNA levels were determined after 4 h by Northern blot analysis. In other experiments, Caco-2 cells were transfected with a mutant IkappaBalpha in which serines 32 and 36 were substituted by alanine. This mutation prevents IkBalpha phosphorylation and subsequent NF-kappaB nuclear translocation. After transfection, the cells were stimulated with IL-1beta, and C3 levels in the culture medium were measured after 24 h. Cytosolic IkappaBalpha was determined by Western blot analysis. RESULTS: TLCK, genistein, and LLnL each inhibited IL-1beta-induced C3 production in a dose-dependent fashion. These responses were associated with decreased C3 mRNA levels. In contrast, PDTC did not influence C3 production or C3 mRNA in the Caco-2 cells. Transfection of the Caco-2 cells with the Ser 32/36 mutant IkBalpha resulted in maintained IkappaBalpha levels and decreased IL-beta-induced C3 production. CONCLUSIONS: IL-1beta-stimulated C3 production in the enterocyte may be regulated by NF-kappaB. Copyright 1999 Academic Press.
BACKGROUND: Recent studies suggest that interleukin-1beta (IL-1beta) stimulates the production of the acute phase protein complement component C3 in human intestinal epithelial cells. The transcription factor NF-kappaB activates different genes involved in the response to cytokines. It is not known if IL-1beta-induced C3 production in the enterocyte is regulated by NF-kappaB. MATERIALS AND METHODS: Cultured Caco-2 cells, a human intestinal epithelial cell line, were treated with one of the NF-kappaB inhibitors, tosyl-lys-chloromethylketone (TLCK), genistein, or pyrrolidine dithiocarbamate (PDTC), or with N-acetyl-leu-leu-norleucinal (LLnL), a proteasome inhibitor known to block the degradation of Ikappabeta, the cytosolic inhibitor of NF-kappaB. Following this treatment, the Caco-2 cells were stimulated with IL-1beta, and C3 levels in the culture medium were measured after 24 h by ELISA. C3 mRNA levels were determined after 4 h by Northern blot analysis. In other experiments, Caco-2 cells were transfected with a mutant IkappaBalpha in which serines 32 and 36 were substituted by alanine. This mutation prevents IkBalpha phosphorylation and subsequent NF-kappaB nuclear translocation. After transfection, the cells were stimulated with IL-1beta, and C3 levels in the culture medium were measured after 24 h. Cytosolic IkappaBalpha was determined by Western blot analysis. RESULTS: TLCK, genistein, and LLnL each inhibited IL-1beta-induced C3 production in a dose-dependent fashion. These responses were associated with decreased C3 mRNA levels. In contrast, PDTC did not influence C3 production or C3 mRNA in the Caco-2 cells. Transfection of the Caco-2 cells with the Ser 32/36 mutant IkBalpha resulted in maintained IkappaBalpha levels and decreased IL-beta-induced C3 production. CONCLUSIONS:IL-1beta-stimulated C3 production in the enterocyte may be regulated by NF-kappaB. Copyright 1999 Academic Press.
Authors: Sara L Hall; Theresa Baker; Stephane Lajoie; Phoebe K Richgels; Yanfen Yang; Jaclyn W McAlees; Adelaide van Lier; Marsha Wills-Karp; Umasundari Sivaprasad; Thomas H Acciani; Timothy D LeCras; Jocelyn Biagini Myers; Melinda Butsch Kovacic; Ian P Lewkowich Journal: J Allergy Clin Immunol Date: 2016-06-11 Impact factor: 10.793
Authors: Beatriz Beltrán-Beck; Beatriz Romero; Mariana Boadella; Carmen Casal; Javier Bezos; María Mazariegos; MariPaz Martín; Ruth C Galindo; José M Pérez de la Lastra; Margarita Villar; Joseba M Garrido; Iker A Sevilla; Fernando Asensio; Javier Sicilia; Konstantin P Lyashchenko; Lucas Domínguez; Ramón A Juste; José de la Fuente; Christian Gortázar Journal: Clin Vaccine Immunol Date: 2014-06-11
Authors: Jennifer R Peters-Hall; Kristy J Brown; Dinesh K Pillai; Amarel Tomney; Lindsay M Garvin; Xiaofang Wu; Mary C Rose Journal: Am J Respir Cell Mol Biol Date: 2015-07 Impact factor: 6.914
Authors: A E Karlsen; P E Heding; H Frobøse; S G Rønn; M Kruhøffer; T F Orntoft; M Darville; D L Eizirik; F Pociot; J Nerup; T Mandrup-Poulsen; N Billestrup Journal: Diabetologia Date: 2004-12-02 Impact factor: 10.122
Authors: T Sugihara; A Kobori; H Imaeda; T Tsujikawa; K Amagase; K Takeuchi; Y Fujiyama; A Andoh Journal: Clin Exp Immunol Date: 2010-01-19 Impact factor: 4.330
Authors: Dawn J Caster; Erik A Korte; Sambit K Nanda; Kenneth R McLeish; Rebecca K Oliver; Rachel T G'sell; Ryan M Sheehan; Darrell W Freeman; Susan C Coventry; Jennifer A Kelly; Joel M Guthridge; Judith A James; Kathy L Sivils; Marta E Alarcon-Riquelme; R Hal Scofield; Indra Adrianto; Patrick M Gaffney; Anne M Stevens; Barry I Freedman; Carl D Langefeld; Betty P Tsao; Bernardo A Pons-Estel; Chaim O Jacob; Diane L Kamen; Gary S Gilkeson; Elizabeth E Brown; Graciela S Alarcon; Jeffrey C Edberg; Robert P Kimberly; Javier Martin; Joan T Merrill; John B Harley; Kenneth M Kaufman; John D Reveille; Juan-Manuel Anaya; Lindsey A Criswell; Luis M Vila; Michelle Petri; Rosalind Ramsey-Goldman; Sang-Cheol Bae; Susan A Boackle; Timothy J Vyse; Timothy B Niewold; Philip Cohen; David W Powell Journal: J Am Soc Nephrol Date: 2013-08-22 Impact factor: 10.121